Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Angiogenesis: a curse or cure?

K Gupta1, J Zhang

  • 1Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Mayo Mail Code 480, 420 Delaware Street SE, Minneapolis, Minnesota 55455, USA. gupta014@umn.edu

Postgraduate Medical Journal
|April 7, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vivo clonotypic regulation of human myelin basic protein-reactive T cells by T cell vaccination.

Journal of immunology (Baltimore, Md. : 1950)·1995
Same author

Superantigen reactivity of gamma delta T cell clones isolated from patients with multiple sclerosis and controls.

Cellular immunology·1995
Same author

Tissue distribution of cocaine methyl esterase and ethyl transferase activities: correlation with carboxylesterase protein.

The Journal of pharmacology and experimental therapeutics·1995
Same author

Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E.

The American journal of pathology·1995
Same author

Molecular cloning and characterization of NF-IL3A, a transcriptional activator of the human interleukin-3 promoter.

Molecular and cellular biology·1995
Same author

A potential vulnerability locus for schizophrenia on chromosome 6p24-22: evidence for genetic heterogeneity.

Nature genetics·1995

Angiogenesis, the formation of new blood vessels, is vital for development and repair but can drive disease when dysregulated. Vascular endothelial growth factor (VEGF) is a key regulator, with treatments targeting it showing promise but facing challenges with side effects.

Area of Science:

  • Biomedical Science
  • Molecular Biology
  • Pathophysiology

Background:

  • Angiogenesis is crucial for normal physiological processes like development and repair.
  • Dysregulated angiogenesis is implicated in diseases such as cancer, retinopathy, and coronary artery disease.
  • A delicate balance of pro- and anti-angiogenic factors, notably vascular endothelial growth factor (VEGF), controls this process.

Purpose of the Study:

  • To review the critical role of VEGF in regulating angiogenesis.
  • To discuss the development and clinical application of angiogenesis-based therapies, particularly anti-VEGF treatments.
  • To evaluate the benefits and drawbacks of current angiogenesis-based therapeutic strategies.

Main Methods:

  • Literature review of angiogenesis regulators and therapeutic agents.

Related Experiment Videos

  • Analysis of clinical trial data for anti-VEGF therapies.
  • Discussion of approved treatments like bevacizumab and associated challenges.

    • Main Results:

    • VEGF is a primary driver of endothelial cell proliferation, permeability, and survival.
    • Several anti-VEGF therapies are in clinical trials, with bevacizumab approved for colorectal cancer.
    • Significant challenges remain regarding the side effects of anti-angiogenic treatments.

    Conclusions:

    • Angiogenesis is a complex process with therapeutic potential in various diseases.
    • Targeting VEGF offers promising treatment avenues, but managing side effects is critical.
    • Further research is needed to optimize the risk-benefit profile of angiogenesis-based therapies.